Stand in front of a shelf of sleep products and the decision can look easy. One package promises calm, another plays up hemp, and another mixes several ingredients under a bedtime label. For someone spending the evening replaying tomorrow’s responsibilities, a gummy offers a small, manageable task: chew, wait and hope the mind settles. The package cannot tell you whether the science supports it, whether the dose on the label is the dose in the bottle or whether the product will even be legal to sell in two months.
That last part is new. The CBD sleep aisle grew up in a gap between what Congress allowed and what regulators approved, and that gap is about to close in ways most shoppers have not heard about. The gummy is also filling a different gap, one in the health care system, where the treatment doctors recommend first for chronic insomnia is far harder to find than a bottle at the checkout counter.
A Market Built in a Legal Gray Zone
The 2018 Farm Bill legalized hemp, the low-THC form of cannabis, and CBD products flooded gas stations, grocery stores and wellness shops soon after. The Food and Drug Administration never followed with rules that made those products legitimate. The agency’s position is that CBD cannot lawfully be added to foods or dietary supplements, and it describes the market as “large” and “violative.” A gummy is a food. So the most popular format on the shelf exists largely because enforcement never caught up with sales, which is also why so much of the marketing runs through the wellness influencer economy rather than a pharmacy counter.
That gray zone shows up in the products themselves. FDA testing has found many CBD products that did not contain the levels of CBD they claimed, and the agency has investigated reports of contaminants, including THC. CBD and THC are different compounds, and THC is the one that causes the high, according to the National Institute on Drug Abuse. But “hemp” on a label describes a plant category, not a promise about what is inside, and when one gummy blends CBD, melatonin and botanicals, nobody can tell which ingredient did what.
The Shelf Is About to Change
Late last year, Congress rewrote the definition of hemp. Under the new law, a finished hemp product can contain no more than 0.4 milligrams of total THC per container, a limit aimed at intoxicating hemp products but broad enough to reach many full-spectrum CBD gummies, which contain small amounts of THC. The rules were set to take effect Nov. 12, and in September President Trump signed a bill pushing the deadline to Dec. 11, giving Congress a few more weeks to revisit it.
For shoppers, that means the bedtime aisle could look different by the holidays. Brands selling full-spectrum products may have to reformulate or pull them if the deadline holds. None of that changes what the research says about whether CBD helps you sleep, but it does mean the shelf is being reshaped by Congress, not by better evidence, a pattern SSC has tracked as cannabis policy lurches between mainstream and criminal.
The Research Has Not Caught Up With the Marketing
The best sleep evidence is thin. A 2024 randomized pilot trial in the Journal of Clinical Sleep Medicine gave 30 adults with moderate to severe insomnia either 150 milligrams of CBD or a placebo nightly for two weeks, and CBD did not improve insomnia severity compared with placebo. The CBD group did report better well-being and showed improved sleep efficiency on objective measures, but the study was small, short and used CBD taken under the tongue, not a retail gummy. That is a promising signal, not a treatment.
The anxiety research follows the same shape. In a study in the Brazilian Journal of Psychiatry, 57 healthy men took a single dose of 150, 300 or 600 milligrams of CBD or a placebo before a simulated public-speaking test, and only 300 milligrams reduced anxiety compared with placebo. More was not better, which cuts against the “extra strength” logic of retail packaging. A gummy that lists a smaller dose is not what that study tested, so even a shopper who trusts the result is buying a different product at a different dose for a different problem.
The safety questions are clearer than the benefits. The FDA warns that CBD can cause liver injury, can change how other medications work and raises the risk of sedation and drowsiness when combined with alcohol or other drugs that slow brain activity, including some anxiety and sleep medications. Its one approved CBD drug treats certain severe seizure disorders, under medical supervision, and that approval says nothing about a gummy sold for stress.
The Gummy Is Filling a Gap in Care
The American College of Physicians recommends cognitive behavioral therapy for insomnia, or CBT-I, as the first treatment for chronic insomnia in adults. It works by changing the habits and thoughts that keep people awake, and it is not the same as being told to put the phone down. The problem is finding it. A 2016 survey in Behavioral Sleep Medicine counted just 659 behavioral sleep medicine specialists in the United States, with nearly a fifth of them in New York and California and none in 105 of the country’s 167 cities with more than 150,000 people.
That count is a decade old, and digital CBT-I programs have since appeared, but the basic math holds. A gummy requires no appointment and is available at 11 p.m. when the worry starts. Therapy requires a referral, an available provider, insurance that covers it and weeks of effort. When the recommended treatment is scarce and the unproven one is everywhere, people are not being irrational by reaching for the bottle. They are responding to the options in front of them, often while carrying the kind of stress SSC has described as the quiet signals of economic anxiety.
None of this means dismissing someone who says a gummy helped. That improvement is real to the person who finally got some rest, but it cannot tell another shopper whether the same product will work, which ingredient mattered or whether it is safe with their medications. The fairer ask is aimed at the system: honest labels, real oversight and sleep care people can reach without waiting months. Until then, the CBD aisle will keep selling what exhausted people want to hear, and the evidence will keep saying something quieter.